Massive hope for pancreatic cancer pill after trial saw tumours vanish
An early clinical trial has brought rare progress against advanced pancreatic cancer by pairing chemotherapy with a daily targeted pill called daraxonrasib. Among 61 recently diagnosed patients whose cancer had spread, tumours stopped growing in 90% of participants and shrank or disappeared in just over 60%. For roughly 8%—one in 12—tumours became undetectable on CT scans, and some saw no return of the disease over an average 18-month follow-up.
Already approved in the US, daraxonrasib shuts off RAS mutations that drive growth in most pancreatic cancers as well as dozens of others, including lung and ovarian. Trial investigator Dr Wungki Park of Memorial Sloan Kettering Cancer Center noted higher response rates and a near doubling in the duration of disease control, while EORTC–NCI–AACR Symposium 2026 chair Prof Elena Garralda said the combination could significantly improve overall survival.
Cancer Research UK's Dr Sam Godfrey called the approach "drugging the undruggable", and the charity hailed it as the biggest leap forward in decades for a disease that kills about 53,000 people annually in the US and 10,200 in Britain, where 11,500 are diagnosed each year. Even so, doctors stressed the pill is not a cure and longer studies are needed to see if remissions last.
Continue in the app — vote & join in ➔